You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Reparixin L-lysine salt
Biological Activity for Reparixin L-lysine salt
Reparixin L-lysine salt is a potent and noncompetitive CXCR1 and CXCR2 allosteric antagonist (IC50 = 1 nM for inhibition of CXCL8-induced human polymorphonuclear cell migration). Also inhibits migration of rodent neutrophils induced by CXCL1, CXCL2, CXCL8 and CINC-1. Inhibits vascular permeability and neutrophil recruitment in in vivo models of mild and severe ischemia/reperfusion injury. Also selectively depletes cancer stem cells in human breast cancer cell lines and xenograft models.
Technical Data for Reparixin L-lysine salt
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Reparixin L-lysine salt
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|water||2.15||5 with gentle warming|
Preparing Stock Solutions for Reparixin L-lysine salt
The following data is based on the product molecular weight 429.58. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.5 mM||4.66 mL||23.28 mL||46.56 mL|
|2.5 mM||0.93 mL||4.66 mL||9.31 mL|
|5 mM||0.47 mL||2.33 mL||4.66 mL|
|25 mM||0.09 mL||0.47 mL||0.93 mL|
Product Datasheets for Reparixin L-lysine salt
References for Reparixin L-lysine salt
References are publications that support the biological activity of the product.
Bertini et al (2004) Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc.Natl.Acad.Sci.U.S.A. 101 11791 PMID: 15282370
Souza et al (2004) Repertaxin, a novel inhibitor of rat CXCR2 function, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury. Br.J.Pharmacol. 143 132 PMID: 15302676
Ginestier et al (2010) CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J.Clin.Invest. 120 485 PMID: 20051626
If you know of a relevant reference for Reparixin L-lysine salt, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Reparixin L-lysine salt, Reparixin L-lysine salt supplier, repertaxin, CXCR1, CXCR2, chemokine, receptor, antagonists, antagonism, allosteric, noncompetitive, IL-8, CXCL8, interleukin, 8, Repertaxin, L-lysine, salt, Chemokine, CXC, Receptors, Cancer, Stem, Cells, 6957, Tocris Bioscience
Citations for Reparixin L-lysine salt
Citations are publications that use Tocris products.
Currently there are no citations for Reparixin L-lysine salt. Do you know of a great paper that uses Reparixin L-lysine salt from Tocris? Please let us know.
Reviews for Reparixin L-lysine salt
There are currently no reviews for this product. Be the first to review Reparixin L-lysine salt and earn rewards!
Have you used Reparixin L-lysine salt?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Rheumatoid Arthritis Poster
Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.